MX378397B - Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. - Google Patents

Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.

Info

Publication number
MX378397B
MX378397B MX2016012891A MX2016012891A MX378397B MX 378397 B MX378397 B MX 378397B MX 2016012891 A MX2016012891 A MX 2016012891A MX 2016012891 A MX2016012891 A MX 2016012891A MX 378397 B MX378397 B MX 378397B
Authority
MX
Mexico
Prior art keywords
bacteria
ctla
antibodies
combination
immunorregulatory
Prior art date
Application number
MX2016012891A
Other languages
English (en)
Other versions
MX2016012891A (es
Inventor
Bert Vogelstein
Kenneth Kinzler
Kibem Kim
Saurabh Saha
Shibin Zhou
Original Assignee
Univ Johns Hopkins
Biomed Valley Discoveries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Biomed Valley Discoveries Inc filed Critical Univ Johns Hopkins
Publication of MX2016012891A publication Critical patent/MX2016012891A/es
Publication of MX378397B publication Critical patent/MX378397B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a métodos y kits para el tratamiento de tumores sólidos en un sujeto mediante el uso de una combinación de anticuerpos anti-CTLA-4 y/o anti-PD-1 con al menos un miembro del grupo que consiste en una bacteria, producto bacteriano y una entidad inmunorreguladora. En modalidades particulares, las bacterias son bacterias anaeróbicas depletadas en toxinas, tal como Clostridium novyi-NT.
MX2016012891A 2014-03-31 2015-03-31 Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido. MX378397B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461972633P 2014-03-31 2014-03-31
US201462035291P 2014-08-08 2014-08-08
PCT/US2015/023633 WO2015153639A1 (en) 2014-03-31 2015-03-31 Use of bacteria, bacterial products, and other immunoregulatory entities in combination with anti-ctla-4 and/or anti-pd-1 antibodies to treat solid tumor malignancies

Publications (2)

Publication Number Publication Date
MX2016012891A MX2016012891A (es) 2017-10-12
MX378397B true MX378397B (es) 2025-03-10

Family

ID=54241224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012891A MX378397B (es) 2014-03-31 2015-03-31 Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.

Country Status (7)

Country Link
US (2) US12427173B2 (es)
EP (1) EP3125938A4 (es)
JP (6) JP6712952B2 (es)
AU (3) AU2015240884B2 (es)
CA (1) CA2944456C (es)
MX (1) MX378397B (es)
WO (1) WO2015153639A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6723153B2 (ja) 2013-12-05 2020-07-15 アールエフイーエムビー ホールディングス リミテッド ライアビリティ カンパニー 生体内の望ましくない軟部組織を切除するシステム
SG11201604738TA (en) 2013-12-12 2016-07-28 Shanghai Hengrui Pharm Co Ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
KR102128856B1 (ko) 2015-01-30 2020-07-02 알에프이엠비 홀딩스, 엘엘씨 고주파 전기적 막 파괴를 이용하여 생명체의 바람직하지 않은 연조직을 절제하는 시스템
JP7014706B2 (ja) 2015-07-13 2022-02-01 サイトメックス セラピューティクス インコーポレイテッド 抗ｐｄ－１抗体、活性化可能抗ｐｄ－１抗体、およびその使用方法
EP3402517B1 (en) 2016-01-15 2025-08-20 RFEMB Holdings, LLC Immunologic treatment of cancer by using a tumor ablation technic together with a combination of a ctla-4 inhibitor, a pd-1 inhibitor and gm-csf
MX2019003447A (es) 2016-09-27 2019-08-29 Univ Texas Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
US11168326B2 (en) 2017-07-11 2021-11-09 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
NZ771198A (en) 2018-07-11 2024-11-29 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
AU2020225473A1 (en) * 2019-02-22 2021-09-30 Evelo Biosciences, Inc. Bacterial membrane preparations
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
MX2021010273A (es) 2019-02-27 2021-09-23 Actym Therapeutics Inc Bacterias inmunoestimuladoras modificadas para colonizar tumores, celulas inmunitarias residentes de tumor y el microentorno tumoral.
JP2022534981A (ja) * 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
CA3161450A1 (en) 2019-11-12 2021-05-20 Actym Therapeutics, Inc. Immunostimulatory bacteria delivery platforms and their use for delivery of therapeutic products
JP2023539454A (ja) 2020-08-12 2023-09-14 アクティム・セラピューティクス・インコーポレイテッド 免疫刺激細菌ベースのワクチン、治療薬およびｒｎａデリバリープラットフォーム
CN113995835A (zh) * 2021-10-09 2022-02-01 山东新创生物科技有限公司 戈氏梭菌芽孢联合pd-1抗体的应用
EP4429682A2 (en) 2021-11-09 2024-09-18 Actym Therapeutics, Inc. Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
BE794872A (fr) 1972-02-02 1973-08-01 Rhone Poulenc Sa Nouvelles sulfones derivees de dimethyl-1,5 hexadiene-1,5 ylene
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4308689A (en) 1988-09-02 1990-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
ES2330052T3 (es) 1991-03-01 2009-12-03 Dyax Corporation Proteina quimerica que comprende micro-proteinas que tienen dos o mas puentes disulfuro y relaizaciones de las mismas.
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE69230142T2 (de) 1991-05-15 2000-03-09 Cambridge Antibody Technology Ltd. Verfahren zur herstellung von spezifischen bindungspaargliedern
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
DE69334095T2 (de) 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
JPH09500902A (ja) 1993-07-30 1997-01-28 トーマス・ジェファーソン・ユニバーシティ 細胞内免疫感作
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
CA2143491C (en) 1994-03-01 2011-02-22 Yasumasa Ishida A novel peptide related to human programmed cell death and dna encoding it
IL149701A0 (en) * 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
JP4016612B2 (ja) * 2001-06-07 2007-12-05 株式会社日立製作所 ディスク記録方法及びディスク装置
AU2002350235A1 (en) 2001-11-21 2003-06-10 The Johns Hopkins University Combination bacteriolytic therapy for the treatment of tumors
DK2161336T4 (en) * 2005-05-09 2017-04-24 Ono Pharmaceutical Co Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
WO2009100140A1 (en) * 2008-02-04 2009-08-13 Medarex, Inc. Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof
GB2457346B (en) * 2008-02-12 2012-03-28 Scott Cutters Uk Ltd Cutting tools
PL2482849T3 (pl) * 2009-09-30 2018-11-30 Memorial Sloan-Kettering Cancer Center Skojarzona immunoterapia w leczeniu nowotworu
US20130323167A1 (en) 2010-10-21 2013-12-05 The Johns Hopkins University Detecting and treating solid tumors through selective disruption of tumor vasculature
ES2815564T3 (es) * 2013-03-29 2021-03-30 Biomed Valley Discoveries Inc C. novyi para el tratamiento de tumores sólidos en seres humanos

Also Published As

Publication number Publication date
US20170020931A1 (en) 2017-01-26
AU2020230294B2 (en) 2023-02-23
JP2017509662A (ja) 2017-04-06
US12427173B2 (en) 2025-09-30
AU2015240884B2 (en) 2020-06-18
US20250381235A1 (en) 2025-12-18
EP3125938A1 (en) 2017-02-08
JP2023054308A (ja) 2023-04-13
JP2025094092A (ja) 2025-06-24
CA2944456C (en) 2023-10-31
EP3125938A4 (en) 2017-08-23
JP2024028589A (ja) 2024-03-04
JP7431409B2 (ja) 2024-02-15
AU2023202788A1 (en) 2023-05-25
JP2022031434A (ja) 2022-02-18
JP7659753B2 (ja) 2025-04-10
JP2020100672A (ja) 2020-07-02
JP6712952B2 (ja) 2020-06-24
JP7001731B2 (ja) 2022-01-20
AU2020230294A1 (en) 2020-10-15
CA2944456A1 (en) 2015-10-08
MX2016012891A (es) 2017-10-12
WO2015153639A1 (en) 2015-10-08
AU2015240884A1 (en) 2016-10-20
JP7240685B2 (ja) 2023-03-16

Similar Documents

Publication Publication Date Title
MX378397B (es) Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.
EP4219559A3 (en) Antibodies for lilrb2
MX2022008184A (es) Anticuerpos anti pd-1 y anti-lag3 para usarse en el tratamiento de cancer.
ZA202104246B (en) Humanized anti-human-pd-1 antibody
CO2018000992A2 (es) Anticuerpos anti-pd-1 novedosos
EP4249065A3 (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
PE20210289A1 (es) Anti-cd25 para el agotamiento de celulas tumorales especificas
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
AU2017228470A8 (en) Combination therapy with anti-CD73 antibodies
CL2018001512A1 (es) Anticuerpos anti-cd73 humanizados.
MX2017000187A (es) Proteinas de union a cd33 y cd3 biespecificas.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PH12016501366A1 (en) Novel anti-baff antibodies
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MX2018001530A (es) Anticuerpos anti-pd-l1 novedosos.
BR112017003582A2 (pt) anticorpos, composições e usos
EA201890158A1 (ru) Антитела против ntb-a и связанные композиции и способы
AR090973A1 (es) Anticuerpos utiles para el diagnostico del cancer
MX2016012094A (es) Composiciones de anticuerpos para tratamiento tumoral.
EP4406610A3 (en) Treatment of cancer using anti-cd19 chimeric antigen receptor
MX2017015380A (es) Metodos para utilizar proteinas de enlace biespecificas cd3 y cd33.
EP4541819A3 (en) Anti-cd3 epsilon antibodies
MX373308B (es) Composiciones que comprenden anticuerpos anti-cd38 y carfilzomib.
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
MX2018010491A (es) Proceso para la preparacion de un conjugado anticuerpo-rifamicina.